Administration of L-carnitine and mildronate improves endothelial function and decreases mortality in hypertensive Dahl rats

Pharmacological Reports

Volumn 63, Issue 3, 2011, Pages 752-762

  Vilskersts, Reinis ^a   Kuka, Janis ^a,b   Svalbe, Baiba ^a,c   Cirule, Helena ^a   Liepinsh, Edgars ^a   Grinberga, Solveiga ^a   Kalvinsh, Ivars ^a   Dambrova, Maija ^a  

^a LATVIAN INSTITUTE OF ORGANIC SYNTHESIS   (Latvia)

^b RIGA STRADINS UNIVERSITY   (Latvia)

^c UNIVERSITY OF LATVIA   (Latvia)

Author keywords

Dahl salt sensitive rats; Endothelial dysfunction; Hypertension; L carnitine; Mildronate

Indexed keywords

CARNITINE; MILDRONATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIOVASCULAR EFFECT; CONTROLLED STUDY; DAHL SALT SENSITIVE RAT; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MECHANISM; ECHOCARDIOGRAPHY; ENDOTHELIAL DYSFUNCTION; HEART PROTECTION; HEART RATE; HEART VENTRICLE HYPERTROPHY; HEART WEIGHT; HYPERTENSION; MALE; NONHUMAN; RAT; SURVIVAL RATE; SYSTOLIC BLOOD PRESSURE;

EID: 80051530000     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(11)70587-4     Document Type: Article

References (52)

1. Akahira M, Hara A, Abiko Y: Effect of MET-88, a γ-butyrobetaine hydroxylase inhibitor, on myocardial derangements induced by hydrogen peroxide in the isolated perfused rat heart. Fundam Clin Pharmacol, 1997, 11, 356-364. (Pubitemid 27309872)
2. Aoyagi T, Sugiura S, Eto Y, Yonekura K, Matsumoto A, Yokoyama I, Kobayakawa N et al.: Inhibition of carnitine synthesis protects against left ventricular dysfunction in rats with myocardial ischemia. J Cardiovasc Pharmacol, 1997, 30, 468-474. (Pubitemid 27527582)
3. Bartuś M, Łomnicka M, Kostogrys RB, Kaźmierczak P, Watała C, Słomińska EM, Smoleński RT et al.: 1-Methylnicotinamide (MNA) prevents endothelial dysfunction in hypertriglyceridemic and diabetic rats. Pharmacol Rep, 2008, 60, 127-138. (Pubitemid 351586551)
4. Biswas S, Dastidar DG, Roy KS, Pal SK, Biswas TK, Ganguly SB: Complications of hypertension as encountered by primary care physician. J Indian Med Assoc, 2003, 101, 257-259. (Pubitemid 37081920)
5. Bueno R, Varez de SM, Perez-Guerrero C, Gomez-Amores L, Vazquez CM, Herrera MD: L-carnitine and propionyl-L-carnitine improve endothelial dysfunction in spontaneously hypertensive rats: different participation of NO and COX-products. Life Sci, 2005, 77, 2082-2097. (Pubitemid 41140450)
6. Choi SM, Seo MJ, Kang KK, Kim JH, Ahn BO, Yoo M: Beneficial effects of the combination of amlodipine and losartan for lowering blood pressure in spontaneously hypertensive rats. Arch Pharm Res, 2009, 32, 353-358.
7. Dambrova M, Cirule H, Svalbe B, Zvejniece L, Pugovichs O, Zorenko T, Kalvinsh I et al.: Effect of inhibiting carnitine biosynthesis on male rat sexual performance. Physiol Behav, 2008, 95, 341-347.
8. Dambrova M, Liepinsh E, Kalvinsh I: Mildronate: cardioprotective action through carnitine-lowering effect. Trends Cardiovasc Med, 2002, 12, 275-279. (Pubitemid 35286766)
9. de Sotomayor MA, Mingorance C, Rodriguez-Rodriguez R, Marhuenda E, Herrera MD: l-carnitine and its propionate: improvement of endothelial function in SHR through superoxide dismutase-dependent mechanisms. Free Radic Res, 2007, 41, 884-891. (Pubitemid 47180675)
10. Ferrari R, Merli E, Cicchitelli G, Mele D, Fucili A, Ceconi C: Therapeutic effects of L-carnitine and propionyl- L-carnitine on cardiovascular diseases: a review. Ann NY Acad Sci, 2004, 1033, 79-91. (Pubitemid 39656740)
11. Forde P, Scribner AW, Dial R, Loscalzo J, Trolliet MR: Prevention of hypertension and renal dysfunction in Dahl rats by α-tocopherol. J Cardiovasc Pharmacol, 2003, 42, 82-88. (Pubitemid 36791354)
12. Foster DW: The role of the carnitine system in human metabolism. Ann N Y Acad Sci, 2004, 1033, 1-16.
13. Girerd X, Giral P: Risk stratification for the prevention of cardiovascular complications of hypertension. Curr Med Res Opin, 2004, 20, 1137-1142. (Pubitemid 38954476)
14. Grube M, Meyer zu Schwabedissen HE, Prager D, Haney J, Moritz KU, Meissner K, Rosskopf D et al.: Uptake of cardiovascular drugs into the human heart: expression, regulation, and function of the carnitine transporter OCTN2 (SLC22A5). Circulation, 2006, 113, 1114-1122.
15. Hayashi Y, Kirimoto T, Asaka N, Nakano M, Tajima K, Miyake H, Matsuura N: Beneficial effects of MET-88, a γ-butyrobetaine hydroxylase inhibitor in rats with heart failure following myocardial infarction. Eur J Pharmacol, 2000, 395, 217-224. (Pubitemid 30254371)
16. Hayashi Y, Muranaka Y, Kirimoto T, Asaka N, Miyake H, Matsuura N: Effects of MET-88, a γ-butyrobetaine hydroxylase inhibitor, on tissue carnitine and lipid levels in rats. Biol Pharm Bull, 2000, 23, 770-773. (Pubitemid 30435088)
17. Hirooka Y, Kimura Y, Sagara Y, Ito K, Sunagawa K: Effects of valsartan or amlodipine on endothelial function and oxidative stress after one year follow-up in patients with essential hypertension. Clin Exp Hypertens, 2008, 30, 267-276. (Pubitemid 351556172)
18. Inoko M, Kihara Y, Morii I, Fujiwara H, Sasayama S: Transition from compensatory hypertrophy to dilated, failing left ventricles in Dahl salt-sensitive rats. Am J Physiol, 1994, 267, H2471-H2482.
19. Kamei K, Maehara K, Kimura J, Ishibashi T, Maruyama Y: Comprehensive analyses of arrhythmogenic substrates and vulnerability to ventricular tachycardia in left ventricular hypertrophy in salt-sensitive hypertensive rats. Circ J, 2007, 71, 390-396. (Pubitemid 46409544)
20. Klotz S, Hay I, Zhang G, Maurer M, Wang J, Burkhoff D: Development of heart failure in chronic hypertensive Dahl rats: focus on heart failure with preserved ejection fraction. Hypertension, 2006, 47, 901-911. (Pubitemid 44297562)
21. Kushiro T, Mizuno K, Nakaya N, Ohashi Y, Tajima N, Teramoto T, Uchiyama S et al.: Pravastatin for cardiovascular event primary prevention in patients with mild-to-moderate hypertension in the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Study. Hypertension, 2009, 53, 135-141.
22. Kuwajima M, Harashima H, Hayashi M, Ise S, Sei M, Lu K, Kiwada H et al.: Pharmacokinetic analysis of the cardioprotective effect of 3-(2,2,2- trimethylhydrazinium) propionate in mice: inhibition of carnitine transport in kidney. J Pharmacol Exp Ther, 1999, 289, 93-102. (Pubitemid 29156017)
23. Law MR, Morris JK, Wald NJ: Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ, 2009, 338, b1665.
24. Liepinsh E, Vilskersts R, Loca D, Kirjanova O, Pugovichs O, Kalvinsh I, Dambrova M: Mildronate, an inhibitor of carnitine biosynthesis, induces an increase in gamma-butyrobetaine contents and cardioprotection in isolated rat heart infarction. J Cardiovasc Pharmacol, 2006, 48, 314-319. (Pubitemid 46066837)
25. Liepinsh E, Vilskersts R, Skapare E, Svalbe B, Kuka J, Cirule H, Pugovics O et al.: Mildronate decreases carnitine availability and up-regulates glucose uptake and related gene expression in the mouse heart. Life Sci, 2008, 83, 613-619.
26. Liepinsh E, Vilskersts R, Zvejniece L, Svalbe B, Skapare E, Kuka J, Cirule H et al.: Protective effects of mildronate in an experimental model of type 2 diabetes in Goto-Kakizaki rats. Br J Pharmacol, 2009, 157, 1549-1556.
27. Lin KF, Chao J, Chao L: Atrial natriuretic peptide gene delivery reduces stroke-induced mortality rate in Dahl salt-sensitive rats. Hypertension, 1999, 33, 219-224. (Pubitemid 29065663)
28. Messerli FH: Hypertension and sudden cardiac death. Am J Hypertens, 1999, 12, 181S-188S.
29. Miguel-Carrasco JL, Mate A, Monserrat MT, Arias JL, Aramburu O, Vazquez CM: The role of inflammatory markers in the cardioprotective effect of L-carnitine in L-NAME-induced hypertension. Am J Hypertens, 2008, 21, 1231-1237.
30. Mingrone G: Carnitine in type 2 diabetes. Ann NY Acad Sci, 2004, 1033, 99-107.
31. Najafi M, Garjani A, Maleki N, Eteraf OT: Antiarrhythmic and arrhythmogenic effects of L-carnitine in ischemia and reperfusion. Bull Exp Biol Med, 2008, 146, 210-213.
32. O'Brien D, Chunduri P, Iyer A, Brown L: L-carnitine attenuates cardiac remodelling rather than vascular remodelling in deoxycorticosterone acetate-salt hypertensive rats. Basic Clin Pharmacol Toxicol, 2010, 106, 296-301.
33. Palatini P: Heart rate as predictor of outcome. Blood Press Monit, 2008, 13, 167-168.
34. Perticone F, Ceravolo R, Pujia A, Ventura G, Iacopino S, Scozzafava A, Ferraro A et al.: Prognostic significance of endothelial dysfunction in hypertensive patients. Circulation, 2001, 104, 191-196. (Pubitemid 32655837)
35. Qu P, Hamada M, Ikeda S, Hiasa G, Shigematsu Y, Hiwada K: Time-course changes in left ventricular geometry and function during the development of hypertension in Dahl salt-sensitive rats. Hypertens Res, 2000, 23, 613-623. (Pubitemid 32042100)
36. Rajasekar P, Palanisamy N, Anuradha CV: Increase in nitric oxide and reductions in blood pressure, protein kinase C beta II and oxidative stress by L-carnitine: a study in the fructose-fed hypertensive rat. Clin Exp Hypertens, 2007, 29, 517-530. (Pubitemid 350223251)
37. Rebouche CJ, Chenard CA: Metabolic fate of dietary carnitine in human adults: identification and quantification of urinary and fecal metabolites. J Nutr, 1991, 121, 539-546.
38. Sandor A: Butyrobetaine is equal to L-carnitine in elevating L-carnitine levels in rats. Biochim Biophys Acta, 1991, 1083, 135-138.
39. Sayed-Ahmed MM, Khattab MM, Gad MZ, Mostafa N: L-Carnitine prevents the progression of atherosclerotic lesions in hypercholesterolaemic rabbits. Pharmacol Res, 2001, 44, 235-242. (Pubitemid 32889467)
40. Schiffrin EL: Vascular remodeling and endothelial function in hypertensive patients: effects of antihypertensive therapy. Scand Cardiovasc J, Suppl, 1998, 47, 15-21.
41. Sesti C, Simkhovich BZ, Kalvinsh I, Kloner RA: Mildronate, a novel fatty acid oxidation inhibitor and antianginal agent, reduces myocardial infarct size without affecting hemodynamics. J Cardiovasc Pharmacol, 2006, 47, 493-499. (Pubitemid 44309706)
42. Shankar SS, Mirzamohammadi B, Walsh JP, Steinberg HO: L-carnitine may attenuate free fatty acid-induced endothelial dysfunction. Ann NY Acad Sci, 2004, 1033, 189-197.
43. Simkhovich BZ, Shutenko ZV, Meirena DV, Khagi KB, Mezapuke RJ, Molodchina TN, Kalvins IJ et al.: 3-(2,2,2-Trimethylhydrazinium)propionate (THP) - a novel γ-butyrobetaine hydroxylase inhibitor with cardioprotective properties. Biochem Pharmacol, 1988, 37, 195-202.
44. Tanaka N, Katayama Y, Katsumata T, Otori T, Nishiyama Y: Effects of long-term administration of HMG-CoA reductase inhibitor, atorvastatin, on stroke events and local cerebral blood flow in stroke-prone spontaneously hypertensive rats. Brain Res, 2007, 1169, 125-132. (Pubitemid 47381354)
45. Turnbull F: Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet, 2003, 362, 1527-1535.
46. Tzemos N, Lim PO, MacDonald TM: Nebivolol reverses endothelial dysfunction in essential hypertension: a randomized, double-blind, crossover study. Circulation, 2001, 104, 511-514. (Pubitemid 32738117)
47. Vilskersts R, Liepinsh E, Kuka J, Cirule H, Veveris M, Kalvinsh I, Dambrova M: Myocardial infarct size-limiting and anti-arrhythmic effects of mildronate orotate in the rat heart. Cardiovasc Drugs Ther, 2009, 23, 281-288.
48. -/- mice. Pharmacology, 2009, 83, 287-293.
49. Xu JZ, Zhang Y, Wu SN, Niu WQ, Zhu DL, Gao PJ: Impaired endothelial function in hypertensive patients with target organ damage. J Hum Hypertens, 2009, 23, 751-757.
50. Zhou MS, Adam AG, Jaimes EA, Raij L: In salt-sensitive hypertension, increased superoxide production is linked to functional upregulation of angiotensin II. Hypertension, 2003, 42, 945-951. (Pubitemid 37413735)
51. Zhou MS, Jaimes EA, Raij L: Benazepril combined with either amlodipine or hydrochlorothiazide is more effective than monotherapy for blood pressure control and prevention of end-organ injury in hypertensive Dahl rats. J Cardiovasc Pharmacol, 2006, 48, 857-861. (Pubitemid 44276464)
52. Zhu A, Yoneda T, Demura M, Karashima S, Usukura M, Yamagishi M, Takeda Y: Effect of mineralocorticoid receptor blockade on the renal renin-angiotensin system in Dahl salt-sensitive hypertensive rats. J Hypertens, 2009, 27, 800-805.